img

Global Long-acting Recombinant Human Erythropoietin Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Long-acting Recombinant Human Erythropoietin Market Insights, Forecast to 2034

Long-acting erythropoietin (EPO) drugs are a type of medication used to stimulate the production of red blood cells in the body. These drugs are primarily prescribed for individuals with certain medical conditions, such as anemia associated with chronic kidney disease or cancer treatment.
Global Long-acting Recombinant Human Erythropoietin market is expected to reach to US$ 861 million in 2024, with a positive growth of %, compared with US$ 843 million in 2022. Backed with the increasing demand from downstream industries, Long-acting Recombinant Human Erythropoietin industry is evaluated to reach US$ 1102.1 million in 2029. The CAGR will be 4.2% during 2024 to 2029.
Globally, Long-acting Recombinant Human Erythropoietin key manufacturers include Amgen, Johnson & Johnson and Kyowa Kirin, etc. Amgen, Johnson & Johnson, Kyowa Kirin are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Long-acting Recombinant Human Erythropoietin were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Long-acting Recombinant Human Erythropoietin market and estimated to attract more attentions from industry insiders and investors.
Long-acting Recombinant Human Erythropoietin can be divided into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Others, etc. Epoetin-alfa is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Long-acting Recombinant Human Erythropoietin is widely used in various fields, such as Anemia, Kidney Disorders and Others,, etc. Anemia provides greatest supports to the Long-acting Recombinant Human Erythropoietin industry development. In 2022, global % sales of Long-acting Recombinant Human Erythropoietin went into Anemia filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Long-acting Recombinant Human Erythropoietin market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Long-acting Recombinant Human Erythropoietin market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Amgen
Johnson & Johnson
Kyowa Kirin
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others

Segment by Application


Anemia
Kidney Disorders
Others

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Long-acting Recombinant Human Erythropoietin plant distribution, commercial date of Long-acting Recombinant Human Erythropoietin, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Long-acting Recombinant Human Erythropoietin introduction, etc. Long-acting Recombinant Human Erythropoietin Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Long-acting Recombinant Human Erythropoietin
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Long-acting Recombinant Human Erythropoietin Product Introduction
1.2 Market by Type
1.2.1 Global Long-acting Recombinant Human Erythropoietin Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Epoetin-alfa
1.2.3 Epoetin-beta
1.2.4 Darbepoetin-alfa
1.2.5 Others
1.3 Market by Application
1.3.1 Global Long-acting Recombinant Human Erythropoietin Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Anemia
1.3.3 Kidney Disorders
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Long-acting Recombinant Human Erythropoietin Sales Estimates and Forecasts 2018-2029
2.2 Global Long-acting Recombinant Human Erythropoietin Revenue by Region
2.2.1 Global Long-acting Recombinant Human Erythropoietin Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Long-acting Recombinant Human Erythropoietin Revenue by Region (2018-2024)
2.2.3 Global Long-acting Recombinant Human Erythropoietin Revenue by Region (2024-2029)
2.2.4 Global Long-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2018-2029)
2.3 Global Long-acting Recombinant Human Erythropoietin Sales Estimates and Forecasts 2018-2029
2.4 Global Long-acting Recombinant Human Erythropoietin Sales by Region
2.4.1 Global Long-acting Recombinant Human Erythropoietin Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Long-acting Recombinant Human Erythropoietin Sales by Region (2018-2024)
2.4.3 Global Long-acting Recombinant Human Erythropoietin Sales by Region (2024-2029)
2.4.4 Global Long-acting Recombinant Human Erythropoietin Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Long-acting Recombinant Human Erythropoietin Sales by Manufacturers
3.1.1 Global Long-acting Recombinant Human Erythropoietin Sales by Manufacturers (2018-2024)
3.1.2 Global Long-acting Recombinant Human Erythropoietin Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Long-acting Recombinant Human Erythropoietin in 2022
3.2 Global Long-acting Recombinant Human Erythropoietin Revenue by Manufacturers
3.2.1 Global Long-acting Recombinant Human Erythropoietin Revenue by Manufacturers (2018-2024)
3.2.2 Global Long-acting Recombinant Human Erythropoietin Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Long-acting Recombinant Human Erythropoietin Revenue in 2022
3.3 Global Key Players of Long-acting Recombinant Human Erythropoietin, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Long-acting Recombinant Human Erythropoietin Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Long-acting Recombinant Human Erythropoietin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Long-acting Recombinant Human Erythropoietin, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Long-acting Recombinant Human Erythropoietin, Product Offered and Application
3.8 Global Key Manufacturers of Long-acting Recombinant Human Erythropoietin, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Long-acting Recombinant Human Erythropoietin Sales by Type
4.1.1 Global Long-acting Recombinant Human Erythropoietin Historical Sales by Type (2018-2024)
4.1.2 Global Long-acting Recombinant Human Erythropoietin Forecasted Sales by Type (2024-2029)
4.1.3 Global Long-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
4.2 Global Long-acting Recombinant Human Erythropoietin Revenue by Type
4.2.1 Global Long-acting Recombinant Human Erythropoietin Historical Revenue by Type (2018-2024)
4.2.2 Global Long-acting Recombinant Human Erythropoietin Forecasted Revenue by Type (2024-2029)
4.2.3 Global Long-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
4.3 Global Long-acting Recombinant Human Erythropoietin Price by Type
4.3.1 Global Long-acting Recombinant Human Erythropoietin Price by Type (2018-2024)
4.3.2 Global Long-acting Recombinant Human Erythropoietin Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Long-acting Recombinant Human Erythropoietin Sales by Application
5.1.1 Global Long-acting Recombinant Human Erythropoietin Historical Sales by Application (2018-2024)
5.1.2 Global Long-acting Recombinant Human Erythropoietin Forecasted Sales by Application (2024-2029)
5.1.3 Global Long-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
5.2 Global Long-acting Recombinant Human Erythropoietin Revenue by Application
5.2.1 Global Long-acting Recombinant Human Erythropoietin Historical Revenue by Application (2018-2024)
5.2.2 Global Long-acting Recombinant Human Erythropoietin Forecasted Revenue by Application (2024-2029)
5.2.3 Global Long-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
5.3 Global Long-acting Recombinant Human Erythropoietin Price by Application
5.3.1 Global Long-acting Recombinant Human Erythropoietin Price by Application (2018-2024)
5.3.2 Global Long-acting Recombinant Human Erythropoietin Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Long-acting Recombinant Human Erythropoietin Market Size by Type
6.1.1 US & Canada Long-acting Recombinant Human Erythropoietin Sales by Type (2018-2029)
6.1.2 US & Canada Long-acting Recombinant Human Erythropoietin Revenue by Type (2018-2029)
6.2 US & Canada Long-acting Recombinant Human Erythropoietin Market Size by Application
6.2.1 US & Canada Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
6.2.2 US & Canada Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
6.3 US & Canada Long-acting Recombinant Human Erythropoietin Market Size by Country
6.3.1 US & Canada Long-acting Recombinant Human Erythropoietin Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Long-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
6.3.3 US & Canada Long-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Long-acting Recombinant Human Erythropoietin Market Size by Type
7.1.1 Europe Long-acting Recombinant Human Erythropoietin Sales by Type (2018-2029)
7.1.2 Europe Long-acting Recombinant Human Erythropoietin Revenue by Type (2018-2029)
7.2 Europe Long-acting Recombinant Human Erythropoietin Market Size by Application
7.2.1 Europe Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
7.2.2 Europe Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
7.3 Europe Long-acting Recombinant Human Erythropoietin Market Size by Country
7.3.1 Europe Long-acting Recombinant Human Erythropoietin Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Long-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
7.3.3 Europe Long-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Long-acting Recombinant Human Erythropoietin Market Size
8.1.1 China Long-acting Recombinant Human Erythropoietin Sales (2018-2029)
8.1.2 China Long-acting Recombinant Human Erythropoietin Revenue (2018-2029)
8.2 China Long-acting Recombinant Human Erythropoietin Market Size by Application
8.2.1 China Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
8.2.2 China Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Long-acting Recombinant Human Erythropoietin Market Size by Type
9.1.1 Asia Long-acting Recombinant Human Erythropoietin Sales by Type (2018-2029)
9.1.2 Asia Long-acting Recombinant Human Erythropoietin Revenue by Type (2018-2029)
9.2 Asia Long-acting Recombinant Human Erythropoietin Market Size by Application
9.2.1 Asia Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
9.2.2 Asia Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
9.3 Asia Long-acting Recombinant Human Erythropoietin Sales by Region
9.3.1 Asia Long-acting Recombinant Human Erythropoietin Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Long-acting Recombinant Human Erythropoietin Revenue by Region (2018-2029)
9.3.3 Asia Long-acting Recombinant Human Erythropoietin Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Market Size by Type
10.1.1 Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Market Size by Application
10.2.1 Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales by Country
10.3.1 Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Information
11.1.2 Amgen Overview
11.1.3 Amgen Long-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Amgen Long-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Amgen Recent Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Overview
11.2.3 Johnson & Johnson Long-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Johnson & Johnson Long-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Johnson & Johnson Recent Developments
11.3 Kyowa Kirin
11.3.1 Kyowa Kirin Company Information
11.3.2 Kyowa Kirin Overview
11.3.3 Kyowa Kirin Long-acting Recombinant Human Erythropoietin Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Kyowa Kirin Long-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Kyowa Kirin Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Long-acting Recombinant Human Erythropoietin Industry Chain Analysis
12.2 Long-acting Recombinant Human Erythropoietin Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Long-acting Recombinant Human Erythropoietin Production Mode & Process
12.4 Long-acting Recombinant Human Erythropoietin Sales and Marketing
12.4.1 Long-acting Recombinant Human Erythropoietin Sales Channels
12.4.2 Long-acting Recombinant Human Erythropoietin Distributors
12.5 Long-acting Recombinant Human Erythropoietin Customers
13 Market Dynamics
13.1 Long-acting Recombinant Human Erythropoietin Industry Trends
13.2 Long-acting Recombinant Human Erythropoietin Market Drivers
13.3 Long-acting Recombinant Human Erythropoietin Market Challenges
13.4 Long-acting Recombinant Human Erythropoietin Market Restraints
14 Key Findings in The Global Long-acting Recombinant Human Erythropoietin Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Long-acting Recombinant Human Erythropoietin Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Epoetin-alfa
Table 3. Major Manufacturers of Epoetin-beta
Table 4. Major Manufacturers of Darbepoetin-alfa
Table 5. Major Manufacturers of Others
Table 6. Global Long-acting Recombinant Human Erythropoietin Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Long-acting Recombinant Human Erythropoietin Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Long-acting Recombinant Human Erythropoietin Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Long-acting Recombinant Human Erythropoietin Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Long-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2018-2024)
Table 11. Global Long-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2024-2029)
Table 12. Global Long-acting Recombinant Human Erythropoietin Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Long-acting Recombinant Human Erythropoietin Sales by Region (2018-2024) & (K Units)
Table 14. Global Long-acting Recombinant Human Erythropoietin Sales by Region (2024-2029) & (K Units)
Table 15. Global Long-acting Recombinant Human Erythropoietin Sales Market Share by Region (2018-2024)
Table 16. Global Long-acting Recombinant Human Erythropoietin Sales Market Share by Region (2024-2029)
Table 17. Global Long-acting Recombinant Human Erythropoietin Sales by Manufacturers (2018-2024) & (K Units)
Table 18. Global Long-acting Recombinant Human Erythropoietin Sales Share by Manufacturers (2018-2024)
Table 19. Global Long-acting Recombinant Human Erythropoietin Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Long-acting Recombinant Human Erythropoietin Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Long-acting Recombinant Human Erythropoietin, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Long-acting Recombinant Human Erythropoietin Price by Manufacturers 2018-2024 (US$/Unit)
Table 23. Global Long-acting Recombinant Human Erythropoietin Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Long-acting Recombinant Human Erythropoietin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Recombinant Human Erythropoietin as of 2022)
Table 25. Global Key Manufacturers of Long-acting Recombinant Human Erythropoietin, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Long-acting Recombinant Human Erythropoietin, Product Offered and Application
Table 27. Global Key Manufacturers of Long-acting Recombinant Human Erythropoietin, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Long-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 30. Global Long-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 31. Global Long-acting Recombinant Human Erythropoietin Sales Share by Type (2018-2024)
Table 32. Global Long-acting Recombinant Human Erythropoietin Sales Share by Type (2024-2029)
Table 33. Global Long-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Long-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Long-acting Recombinant Human Erythropoietin Revenue Share by Type (2018-2024)
Table 36. Global Long-acting Recombinant Human Erythropoietin Revenue Share by Type (2024-2029)
Table 37. Long-acting Recombinant Human Erythropoietin Price by Type (2018-2024) & (US$/Unit)
Table 38. Global Long-acting Recombinant Human Erythropoietin Price Forecast by Type (2024-2029) & (US$/Unit)
Table 39. Global Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 40. Global Long-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 41. Global Long-acting Recombinant Human Erythropoietin Sales Share by Application (2018-2024)
Table 42. Global Long-acting Recombinant Human Erythropoietin Sales Share by Application (2024-2029)
Table 43. Global Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Long-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Long-acting Recombinant Human Erythropoietin Revenue Share by Application (2018-2024)
Table 46. Global Long-acting Recombinant Human Erythropoietin Revenue Share by Application (2024-2029)
Table 47. Long-acting Recombinant Human Erythropoietin Price by Application (2018-2024) & (US$/Unit)
Table 48. Global Long-acting Recombinant Human Erythropoietin Price Forecast by Application (2024-2029) & (US$/Unit)
Table 49. US & Canada Long-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 50. US & Canada Long-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 51. US & Canada Long-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Long-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 54. US & Canada Long-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 55. US & Canada Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Long-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Long-acting Recombinant Human Erythropoietin Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Long-acting Recombinant Human Erythropoietin Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Long-acting Recombinant Human Erythropoietin Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Long-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 61. US & Canada Long-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 62. Europe Long-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 63. Europe Long-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 64. Europe Long-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Long-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 67. Europe Long-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 68. Europe Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Long-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Long-acting Recombinant Human Erythropoietin Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Long-acting Recombinant Human Erythropoietin Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Long-acting Recombinant Human Erythropoietin Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Long-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 74. Europe Long-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 75. China Long-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 76. China Long-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 77. China Long-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Long-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 80. China Long-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 81. China Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Long-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Long-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 84. Asia Long-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 85. Asia Long-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Long-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 88. Asia Long-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 89. Asia Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Long-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Long-acting Recombinant Human Erythropoietin Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Long-acting Recombinant Human Erythropoietin Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Long-acting Recombinant Human Erythropoietin Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Long-acting Recombinant Human Erythropoietin Sales by Region (2018-2024) & (K Units)
Table 95. Asia Long-acting Recombinant Human Erythropoietin Sales by Region (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales by Type (2018-2024) & (K Units)
Table 97. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales by Type (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales by Application (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales by Application (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales by Country (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales by Country (2024-2029) & (K Units)
Table 109. Amgen Company Information
Table 110. Amgen Description and Major Businesses
Table 111. Amgen Long-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Amgen Long-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Amgen Recent Developments
Table 114. Johnson & Johnson Company Information
Table 115. Johnson & Johnson Description and Major Businesses
Table 116. Johnson & Johnson Long-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Johnson & Johnson Long-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Johnson & Johnson Recent Developments
Table 119. Kyowa Kirin Company Information
Table 120. Kyowa Kirin Description and Major Businesses
Table 121. Kyowa Kirin Long-acting Recombinant Human Erythropoietin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Kyowa Kirin Long-acting Recombinant Human Erythropoietin Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Kyowa Kirin Recent Developments
Table 124. Key Raw Materials Lists
Table 125. Raw Materials Key Suppliers Lists
Table 126. Long-acting Recombinant Human Erythropoietin Distributors List
Table 127. Long-acting Recombinant Human Erythropoietin Customers List
Table 128. Long-acting Recombinant Human Erythropoietin Market Trends
Table 129. Long-acting Recombinant Human Erythropoietin Market Drivers
Table 130. Long-acting Recombinant Human Erythropoietin Market Challenges
Table 131. Long-acting Recombinant Human Erythropoietin Market Restraints
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Long-acting Recombinant Human Erythropoietin Product Picture
Figure 2. Global Long-acting Recombinant Human Erythropoietin Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Long-acting Recombinant Human Erythropoietin Market Share by Type in 2022 & 2029
Figure 4. Epoetin-alfa Product Picture
Figure 5. Epoetin-beta Product Picture
Figure 6. Darbepoetin-alfa Product Picture
Figure 7. Others Product Picture
Figure 8. Global Long-acting Recombinant Human Erythropoietin Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Long-acting Recombinant Human Erythropoietin Market Share by Application in 2022 & 2029
Figure 10. Anemia
Figure 11. Kidney Disorders
Figure 12. Others
Figure 13. Long-acting Recombinant Human Erythropoietin Report Years Considered
Figure 14. Global Long-acting Recombinant Human Erythropoietin Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Long-acting Recombinant Human Erythropoietin Revenue 2018-2029 (US$ Million)
Figure 16. Global Long-acting Recombinant Human Erythropoietin Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global Long-acting Recombinant Human Erythropoietin Revenue Market Share by Region (2018-2029)
Figure 18. Global Long-acting Recombinant Human Erythropoietin Sales 2018-2029 ((K Units)
Figure 19. Global Long-acting Recombinant Human Erythropoietin Sales Market Share by Region (2018-2029)
Figure 20. US & Canada Long-acting Recombinant Human Erythropoietin Sales YoY (2018-2029) & (K Units)
Figure 21. US & Canada Long-acting Recombinant Human Erythropoietin Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe Long-acting Recombinant Human Erythropoietin Sales YoY (2018-2029) & (K Units)
Figure 23. Europe Long-acting Recombinant Human Erythropoietin Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China Long-acting Recombinant Human Erythropoietin Sales YoY (2018-2029) & (K Units)
Figure 25. China Long-acting Recombinant Human Erythropoietin Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) Long-acting Recombinant Human Erythropoietin Sales YoY (2018-2029) & (K Units)
Figure 27. Asia (excluding China) Long-acting Recombinant Human Erythropoietin Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales YoY (2018-2029) & (K Units)
Figure 29. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The Long-acting Recombinant Human Erythropoietin Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Long-acting Recombinant Human Erythropoietin in the World: Market Share by Long-acting Recombinant Human Erythropoietin Revenue in 2022
Figure 32. Global Long-acting Recombinant Human Erythropoietin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Long-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 34. Global Long-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 35. Global Long-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 36. Global Long-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada Long-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 38. US & Canada Long-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 39. US & Canada Long-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 40. US & Canada Long-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 41. US & Canada Long-acting Recombinant Human Erythropoietin Revenue Share by Country (2018-2029)
Figure 42. US & Canada Long-acting Recombinant Human Erythropoietin Sales Share by Country (2018-2029)
Figure 43. U.S. Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 44. Canada Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 45. Europe Long-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 46. Europe Long-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 47. Europe Long-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 48. Europe Long-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 49. Europe Long-acting Recombinant Human Erythropoietin Revenue Share by Country (2018-2029)
Figure 50. Europe Long-acting Recombinant Human Erythropoietin Sales Share by Country (2018-2029)
Figure 51. Germany Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 52. France Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 53. U.K. Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 54. Italy Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 55. Russia Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 56. China Long-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 57. China Long-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 58. China Long-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 59. China Long-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 60. Asia Long-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 61. Asia Long-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 62. Asia Long-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 63. Asia Long-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 64. Asia Long-acting Recombinant Human Erythropoietin Revenue Share by Region (2018-2029)
Figure 65. Asia Long-acting Recombinant Human Erythropoietin Sales Share by Region (2018-2029)
Figure 66. Japan Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 67. South Korea Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 68. China Taiwan Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 69. Southeast Asia Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 70. India Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Revenue Share by Country (2018-2029)
Figure 76. Middle East, Africa and Latin America Long-acting Recombinant Human Erythropoietin Sales Share by Country (2018-2029)
Figure 77. Brazil Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 78. Mexico Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 79. Turkey Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 80. Israel Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 81. GCC Countries Long-acting Recombinant Human Erythropoietin Revenue (2018-2029) & (US$ Million)
Figure 82. Long-acting Recombinant Human Erythropoietin Value Chain
Figure 83. Long-acting Recombinant Human Erythropoietin Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries